Floatz logo

Trifluorouracil Tepidopyrimidine

Colorectal Cancer Metastatic

Sun Yat-sen UniversityPhase 2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
65/ 100

Competitive context

64 Active assets in the Colorectal Cancer Metastatic cohort.

Asset / SponsorPhaseRating
Binimetinib
Pierre Fabre Medicament
Phase 3BB
Irinotecan
Oncolytics Biotech
Phase 4BB
Aflibercept
Sanofi
Phase 3BB
Inno-206
Northwell Health
Phase 4B
Durvalumab
University of Iowa
Phase 2B

View all 50 →

Same molecule, other indications

Trifluorouracil Tepidopyrimidine is also rated in:

cancerDormant
CCC
Indicative ·
53 / 100
View asset →
Targeted TherapyDormant
CCC
Indicative ·
53 / 100
View asset →
Radiotherapy, Intensity-ModulatedDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →